The Mainz Severity Score Index (MSSI): development and validation of a system for scoring the signs and symptoms of Fabry disease

被引：41
|
作者：
Beck, M [1 ]
机构：
[1] Univ Mainz, Childrens Hosp, D-6500 Mainz, Germany
来源：
ACTA PAEDIATRICA | 2006年 / 95卷
关键词：
Fabry disease; MSSI;
D O I：
10.1080/08035320600618825
中图分类号：
R72 [儿科学];
学科分类号：
100202 ;
摘要：
Fabry disease is a rare lysosomal storage disorder caused by the deficient activity of the lysosomal enzyme a-galactosidase A. The resultant storage of undegraded glycolipids leads to the progressive development of potentially life-threatening manifestations affecting multiple organ systems in the body. This paper describes the development of the Mainz Severity Score Index (MSSI), a scoring system for patients with Fabry disease. Conclusion: The MSSI score has been proven to be representative in patients with 'classic' Fabry disease and may be useful for monitoring clinical improvement in patients receiving enzyme replacement therapy.
引用
收藏
页码：43 / 46
页数：4
相关论文
共 50 条
  • [21] Development and validation of the International Hidradenitis Suppurativa Severity Score System (IHS4), a novel dynamic scoring system to assess HS severity
    Zouboulis, C. C.
    Tzellos, T.
    Kyrgidis, A.
    Jemec, G. B. E.
    Bechara, F. G.
    Giamarellos-Bourboulis, E. J.
    Ingram, J. R.
    Kanni, T.
    Karagiannidis, I.
    Martorell, A.
    Matusiak, L.
    Pinter, A.
    Prens, E. P.
    Presser, D.
    Schneider-Burrus, S.
    von Stebut, E.
    Szepietowski, J. C.
    van der Zee, H. H.
    Wilden, S. M.
    Sabat, R.
    BRITISH JOURNAL OF DERMATOLOGY, 2017, 177 (05) : 1401 - 1409
  • [22] Development of a disease severity scoring system for patients with Pompe disease
    Giannim, E. H.
    Berger, K.
    van der Ploeg, A.
    Case, L.
    Dandrea, C.
    Kishnani, P. S.
    Marsden, D.
    JOURNAL OF INHERITED METABOLIC DISEASE, 2008, 31 : 130 - 130
  • [23] Development of a disease severity scoring system for patients with Pompe disease
    Marsden, Deborah
    Berger, Kenneth
    van der Ploeg, Ans
    Case, Laura
    Dandrea, Christopher
    Kishnani, Priya
    Giannini, Edward
    MOLECULAR GENETICS AND METABOLISM, 2008, 93 (02) : S30 - S31
  • [24] Development of a disease severity scoring system for patients with Pompe disease
    E Giannini
    K Berger
    A van der Ploeg
    L Case
    C Dandrea
    P Kishnani
    D Marsden
    Pediatric Rheumatology, 6 (Suppl 1)
  • [25] Development of a disease severity scoring system for patients with Pompe disease
    Giannini, E.
    Van der Ploeg, A. T.
    Berger, K.
    Case, L.
    Dandrea, C.
    Kishnani, P. S.
    Marsden, D. L.
    JOURNAL OF INHERITED METABOLIC DISEASE, 2007, 30 : 108 - 108
  • [26] Development of a disease severity scoring system for patients with Pompe disease
    Giannini, E.
    Berger, K.
    van der Ploeg, A.
    Case, L.
    Dandrea, C.
    Kishnani, P.
    Marsden, D.
    CLINICAL THERAPEUTICS, 2008, 30 : S28 - S28
  • [27] Disease severity scoring system for acid sphingomyelinase deficiency: Severity score domains and components
    Cassiman, David
    Cappellini, Maria Domenica
    Mabe, Paulina
    Polkey, Michael I.
    Schiano, Thomas
    Vanier, Marie
    Wasserstein, Melissa P.
    MOLECULAR GENETICS AND METABOLISM, 2018, 123 (02) : S29 - S29
  • [28] Validation of HS4 scoring system and development and validation of a novel scoring system to assess hidradenitis suppurativa severity
    Tzellos, T.
    EXPERIMENTAL DERMATOLOGY, 2017, 26 : 27 - 27
  • [29] Correlation between interleukin-6 promoter and C-reactive protein (CRP) polymorphisms and CRP levels with the Mainz Severity Score Index for Fabry disease
    Altarescu, G.
    Chicco, G.
    Whybra, C.
    Delgado-Sanchez, S.
    Sharon, N.
    Beck, M.
    Elstein, D.
    JOURNAL OF INHERITED METABOLIC DISEASE, 2008, 31 (01) : 117 - 123
  • [30] Changes in left ventricular posterior wall thickness after treatment with enzyme replacement therapy and effect upon the Mainz Severity Score Index in patients with Fabry disease
    Holmes, A. M.
    Reed, M. C.
    Baker, R. J.
    Jeevaratnam, P.
    Mehta, A. B.
    Hughes, D. A.
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2009, 47 : S140 - S140
12345